Allergy to Polyethilenglicole of Anti-SARS CoV2 Vaccine Recipient: A Case Report of Young Adult Recipient and the Management of Future Exposure to SARS-CoV2
The main contraindication to the anti-SARS CoV2 vaccine is an anaphylactic reaction to a vaccine component. The need to vaccinate allergic people who are at higher risk can be of public health interest and this report shows a case of an allergic reaction to PEG of a HCW who had received the first do...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-04-01
|
| Series: | Vaccines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-393X/9/5/412 |
| _version_ | 1827694543040937984 |
|---|---|
| author | Vincenzo Restivo Giuseppina Candore Maria Barrale Ester Caravello Giorgio Graziano Rosa Onida Maurizio Raineri Salvatore Tiralongo Ignazio Brusca |
| author_facet | Vincenzo Restivo Giuseppina Candore Maria Barrale Ester Caravello Giorgio Graziano Rosa Onida Maurizio Raineri Salvatore Tiralongo Ignazio Brusca |
| author_sort | Vincenzo Restivo |
| collection | DOAJ |
| description | The main contraindication to the anti-SARS CoV2 vaccine is an anaphylactic reaction to a vaccine component. The need to vaccinate allergic people who are at higher risk can be of public health interest and this report shows a case of an allergic reaction to PEG of a HCW who had received the first dose of anti-SARS CoV2 vaccine. For 5 h after the administration of the vaccine, she had the appearance of erythematous spots on the face and neck, and a feeling of a slurred mouth and hoarseness. In order to treat the event, she was administered 8 mg intravenous dexamethasone, 1 vial intravenous chlorphenamine maleate, 250 mL intravenous 0.9% NaCl, and conventional oxygen therapy (2 L/min) with complete resolution of the suspected adverse drug reaction. According to the contraindication to the cutaneous test for this patient, BAT was used for further investigations. The patient who suffered the adverse reaction to the COVID-19 vaccine and other five allergic patients who did not report any adverse reaction after the vaccination were tested. There was a significant activation of the vaccine-reactive patient’s basophils with 14.79 CD203chigh% at the concentration of 0.2 mg/mL, while other patients were negative. People who have a confirmed reaction to a vaccine component should undergo further investigation to discover other possible cross-reactions and select the right vaccine to immunize them. |
| first_indexed | 2024-03-10T12:07:25Z |
| format | Article |
| id | doaj.art-2d3c871974c043c8a471ae3cf735478b |
| institution | Directory Open Access Journal |
| issn | 2076-393X |
| language | English |
| last_indexed | 2024-03-10T12:07:25Z |
| publishDate | 2021-04-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Vaccines |
| spelling | doaj.art-2d3c871974c043c8a471ae3cf735478b2023-11-21T16:28:06ZengMDPI AGVaccines2076-393X2021-04-019541210.3390/vaccines9050412Allergy to Polyethilenglicole of Anti-SARS CoV2 Vaccine Recipient: A Case Report of Young Adult Recipient and the Management of Future Exposure to SARS-CoV2Vincenzo Restivo0Giuseppina Candore1Maria Barrale2Ester Caravello3Giorgio Graziano4Rosa Onida5Maurizio Raineri6Salvatore Tiralongo7Ignazio Brusca8Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, University of Palermo, 90127 Palermo, ItalyDepartment of Biomedicine, Neurosciences and Advanced Diagnostics, University of Palermo, 90127 Palermo, ItalyLaboratory of Clinical Pathology, “Buccheri La Ferla” Hospital, 90127 Palermo, ItalyDepartment of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, University of Palermo, 90127 Palermo, ItalyDepartment of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, University of Palermo, 90127 Palermo, ItalyLaboratory of Clinical Pathology, “Buccheri La Ferla” Hospital, 90127 Palermo, ItalyDepartment of Biopathology and Medical Biotechnologies, University of Palermo, 90127 Palermo, ItalyDepartment of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, University of Palermo, 90127 Palermo, ItalyLaboratory of Clinical Pathology, “Buccheri La Ferla” Hospital, 90127 Palermo, ItalyThe main contraindication to the anti-SARS CoV2 vaccine is an anaphylactic reaction to a vaccine component. The need to vaccinate allergic people who are at higher risk can be of public health interest and this report shows a case of an allergic reaction to PEG of a HCW who had received the first dose of anti-SARS CoV2 vaccine. For 5 h after the administration of the vaccine, she had the appearance of erythematous spots on the face and neck, and a feeling of a slurred mouth and hoarseness. In order to treat the event, she was administered 8 mg intravenous dexamethasone, 1 vial intravenous chlorphenamine maleate, 250 mL intravenous 0.9% NaCl, and conventional oxygen therapy (2 L/min) with complete resolution of the suspected adverse drug reaction. According to the contraindication to the cutaneous test for this patient, BAT was used for further investigations. The patient who suffered the adverse reaction to the COVID-19 vaccine and other five allergic patients who did not report any adverse reaction after the vaccination were tested. There was a significant activation of the vaccine-reactive patient’s basophils with 14.79 CD203chigh% at the concentration of 0.2 mg/mL, while other patients were negative. People who have a confirmed reaction to a vaccine component should undergo further investigation to discover other possible cross-reactions and select the right vaccine to immunize them.https://www.mdpi.com/2076-393X/9/5/412SARS CoV2vaccinePEGadverse reactionm-RNA vaccineanaphylaxis |
| spellingShingle | Vincenzo Restivo Giuseppina Candore Maria Barrale Ester Caravello Giorgio Graziano Rosa Onida Maurizio Raineri Salvatore Tiralongo Ignazio Brusca Allergy to Polyethilenglicole of Anti-SARS CoV2 Vaccine Recipient: A Case Report of Young Adult Recipient and the Management of Future Exposure to SARS-CoV2 Vaccines SARS CoV2 vaccine PEG adverse reaction m-RNA vaccine anaphylaxis |
| title | Allergy to Polyethilenglicole of Anti-SARS CoV2 Vaccine Recipient: A Case Report of Young Adult Recipient and the Management of Future Exposure to SARS-CoV2 |
| title_full | Allergy to Polyethilenglicole of Anti-SARS CoV2 Vaccine Recipient: A Case Report of Young Adult Recipient and the Management of Future Exposure to SARS-CoV2 |
| title_fullStr | Allergy to Polyethilenglicole of Anti-SARS CoV2 Vaccine Recipient: A Case Report of Young Adult Recipient and the Management of Future Exposure to SARS-CoV2 |
| title_full_unstemmed | Allergy to Polyethilenglicole of Anti-SARS CoV2 Vaccine Recipient: A Case Report of Young Adult Recipient and the Management of Future Exposure to SARS-CoV2 |
| title_short | Allergy to Polyethilenglicole of Anti-SARS CoV2 Vaccine Recipient: A Case Report of Young Adult Recipient and the Management of Future Exposure to SARS-CoV2 |
| title_sort | allergy to polyethilenglicole of anti sars cov2 vaccine recipient a case report of young adult recipient and the management of future exposure to sars cov2 |
| topic | SARS CoV2 vaccine PEG adverse reaction m-RNA vaccine anaphylaxis |
| url | https://www.mdpi.com/2076-393X/9/5/412 |
| work_keys_str_mv | AT vincenzorestivo allergytopolyethilenglicoleofantisarscov2vaccinerecipientacasereportofyoungadultrecipientandthemanagementoffutureexposuretosarscov2 AT giuseppinacandore allergytopolyethilenglicoleofantisarscov2vaccinerecipientacasereportofyoungadultrecipientandthemanagementoffutureexposuretosarscov2 AT mariabarrale allergytopolyethilenglicoleofantisarscov2vaccinerecipientacasereportofyoungadultrecipientandthemanagementoffutureexposuretosarscov2 AT estercaravello allergytopolyethilenglicoleofantisarscov2vaccinerecipientacasereportofyoungadultrecipientandthemanagementoffutureexposuretosarscov2 AT giorgiograziano allergytopolyethilenglicoleofantisarscov2vaccinerecipientacasereportofyoungadultrecipientandthemanagementoffutureexposuretosarscov2 AT rosaonida allergytopolyethilenglicoleofantisarscov2vaccinerecipientacasereportofyoungadultrecipientandthemanagementoffutureexposuretosarscov2 AT maurizioraineri allergytopolyethilenglicoleofantisarscov2vaccinerecipientacasereportofyoungadultrecipientandthemanagementoffutureexposuretosarscov2 AT salvatoretiralongo allergytopolyethilenglicoleofantisarscov2vaccinerecipientacasereportofyoungadultrecipientandthemanagementoffutureexposuretosarscov2 AT ignaziobrusca allergytopolyethilenglicoleofantisarscov2vaccinerecipientacasereportofyoungadultrecipientandthemanagementoffutureexposuretosarscov2 |